OOIR: Observatory of International Research

Papers

(The TQCC of Seminars in Hematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Iron metabolism in infections: Focus on COVID-19	56
Toward a pathophysiology inspired treatment of VEXAS syndrome	45
Aplastic anemia: Pathophysiology	39
Epidemiology of VITT	36
Platelet-activating anti-PF4 disorders: An overview	34
Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)	33
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome	33
Thrombotic manifestations of VEXAS syndrome	33
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	30
Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization	29
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	26
Genetics of somatic auto-inflammatory disorders	25
VEXAS within the spectrum of rheumatologic disease	23
Shaping the bone through iron and iron-related proteins	19
VEXAS syndrome: An inflammatory and hematologic disease	17
20 years of Hepcidin: How far we have come	17
Laboratory testing for VITT antibodies	13
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	12
Epidemiology and etiology of diffuse large B-cell lymphoma	11
Longitudinal Aspects of VITT	11
Applications of virus-specific T cell therapies post-BMT	11
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	10
Immunosuppressive therapy in severe aplastic anemia	10
TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics	10
Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome	9

Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	9
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multipl	9
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	9
Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges	8
The epidemiology of Waldenström macroglobulinemia	8
The role of viruses in HIV-associated lymphomas	8
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	7
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies	7
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management	7
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies	7
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia	7
Diagnosis and management of adult T-cell leukemia/lymphoma	7
Advances in understanding the crosstalk between mother and fetus on iron utilization	6
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	6
Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin	6
Somatic compensation of inherited bone marrow failure	6
Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies	5
Clinical picture of VITT	5
Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases	5
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	5
Epigenetic activities in erythroid cell gene regulation	5
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy	5
Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria	5
Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells	5
Iron and erythropoiesis: A mutual alliance	5
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	5